Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans

The immunologic basis for the potential enhanced HIV-1 acquisition in Ad5 seropositive individuals who received the Merck rAd5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Kara L., Liu, Jinyan, King, Sharon L., Sun, Ying-Hua, Schmitz, Joern E., Lifton, Michelle A., Hutnick, Natalie A., Betts, Michael R., Dubey, Sheri A., Goudsmit, Jaap, Shiver, John W., Robertson, Michael N., Casimiro, Danilo R., Barouch, Dan H.
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756115/
https://www.ncbi.nlm.nih.gov/pubmed/19620961
http://dx.doi.org/10.1038/nm.1991
_version_ 1782172480164593664
author O’Brien, Kara L.
Liu, Jinyan
King, Sharon L.
Sun, Ying-Hua
Schmitz, Joern E.
Lifton, Michelle A.
Hutnick, Natalie A.
Betts, Michael R.
Dubey, Sheri A.
Goudsmit, Jaap
Shiver, John W.
Robertson, Michael N.
Casimiro, Danilo R.
Barouch, Dan H.
author_facet O’Brien, Kara L.
Liu, Jinyan
King, Sharon L.
Sun, Ying-Hua
Schmitz, Joern E.
Lifton, Michelle A.
Hutnick, Natalie A.
Betts, Michael R.
Dubey, Sheri A.
Goudsmit, Jaap
Shiver, John W.
Robertson, Michael N.
Casimiro, Danilo R.
Barouch, Dan H.
author_sort O’Brien, Kara L.
collection PubMed
description The immunologic basis for the potential enhanced HIV-1 acquisition in Ad5 seropositive individuals who received the Merck rAd5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5 seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5 seronegative subjects following vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
format Text
id pubmed-2756115
institution National Center for Biotechnology Information
language English
publishDate 2009
record_format MEDLINE/PubMed
spelling pubmed-27561152010-02-01 Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans O’Brien, Kara L. Liu, Jinyan King, Sharon L. Sun, Ying-Hua Schmitz, Joern E. Lifton, Michelle A. Hutnick, Natalie A. Betts, Michael R. Dubey, Sheri A. Goudsmit, Jaap Shiver, John W. Robertson, Michael N. Casimiro, Danilo R. Barouch, Dan H. Nat Med Article The immunologic basis for the potential enhanced HIV-1 acquisition in Ad5 seropositive individuals who received the Merck rAd5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5 seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5 seronegative subjects following vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study. 2009-07-20 2009-08 /pmc/articles/PMC2756115/ /pubmed/19620961 http://dx.doi.org/10.1038/nm.1991 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
O’Brien, Kara L.
Liu, Jinyan
King, Sharon L.
Sun, Ying-Hua
Schmitz, Joern E.
Lifton, Michelle A.
Hutnick, Natalie A.
Betts, Michael R.
Dubey, Sheri A.
Goudsmit, Jaap
Shiver, John W.
Robertson, Michael N.
Casimiro, Danilo R.
Barouch, Dan H.
Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
title Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
title_full Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
title_fullStr Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
title_full_unstemmed Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
title_short Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
title_sort adenovirus-specific immunity following immunization with an ad5 hiv-1 vaccine candidate in humans
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756115/
https://www.ncbi.nlm.nih.gov/pubmed/19620961
http://dx.doi.org/10.1038/nm.1991
work_keys_str_mv AT obrienkaral adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT liujinyan adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT kingsharonl adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT sunyinghua adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT schmitzjoerne adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT liftonmichellea adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT hutnicknataliea adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT bettsmichaelr adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT dubeysheria adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT goudsmitjaap adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT shiverjohnw adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT robertsonmichaeln adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT casimirodanilor adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans
AT barouchdanh adenovirusspecificimmunityfollowingimmunizationwithanad5hiv1vaccinecandidateinhumans

Ejemplares similares